Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.

Blood (2025) 146 (Supplement 1): 4066.

https://doi.org/10.1182/blood-2025-4066

Published: 2025

Journal Articles

Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4051.

https://doi.org/10.1182/blood-2025-4051

Published: 2025

Journal Articles

Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma

Blood (2025) 146 (Supplement 1): 930.

https://doi.org/10.1182/blood-2025-930

Published: 2025

Journal Articles

Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma

Blood (2025) 146 (Supplement 1): 2214.

https://doi.org/10.1182/blood-2025-2214

Published: 2025

Journal Articles

Safety and efficacy of talquetamab in patients with relapsed and refractory multiple myeloma (RRMM) with and without renal impairment (RI)

Blood (2025) 146 (Supplement 1): 827.

https://doi.org/10.1182/blood-2025-827

Published: 2025

Journal Articles

Real world outcomes of bispecific T-cell engagers in plasma cell leukemia

Blood (2025) 146 (Supplement 1): 823.

https://doi.org/10.1182/blood-2025-823

Published: 2025

Journal Articles

Oral Care™ kit as a prophylaxis for talquetamab-associated toxicities in patients with Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 7574.

https://doi.org/10.1182/blood-2025-7574

Published: 2025

Journal Articles

ClonoSEQ MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma.

Blood (2025) 146 (Supplement 1): 5846.

https://doi.org/10.1182/blood-2025-5846

Published: 2025

Journal Articles

Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the auriga study

Blood (2025) 146 (Supplement 1): 97.

https://doi.org/10.1182/blood-2025-97

Published: 2025

Journal Articles

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Doris Hansen, Lauren Peres, Danai Dima, Saurabh Zanwar, Omar Alexis Castaneda Puglianini, Alicia Richards, Mahmoud Gaballa, Oren Pasvolsky, Aimaz Afrough, Brett Reid, Ariel Grajales-Cruz, Zhuoer Xie, Utkarsh Goel, Aishwarya Sannareddy, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Hitomi Hosoya, Lekha Mikkilineni, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Peter Cheng, Christian Gordillo, Eli Zolotov, Evguenia Bhurtel, Jeries Kort, Raffaella Cassano Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Rahul Banerjee, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Frederick Locke, Yi Lin, Surbhi Sidana, Krina Patel

Blood (2025) 146 (Supplement 1): 93.

https://doi.org/10.1182/blood-2025-93

Published: 2025

Journal Articles

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Surbhi Sidana, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Alexis Castaneda Puglianini, Gabriel De Avila, Christian Gordillo, Eli Zolotov, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen

Blood (2025) 146 (Supplement 1): 1034.

https://doi.org/10.1182/blood-2025-1034

Published: 2025

Journal Articles

Suppressive dexamethasone (SupDex) to prevent delayed non-icans delayed neurotoxicity (DNT) post ciltacabtagene-autoleucel(cilta-cel) in patients with relapsed myeloma.suppressive dexamethasone (SupDex) to prevent delayed non-icans delayed neurotoxicity (DNT) post ciltacabtagene-autoleucel(cilta-cel) in patients with relapsed myeloma.

Karla Feliciano Salva, Christina Copponex, Junmin Whiting, Doris Hansen, Ciara Louise Freeman, Omar Alexis Castaneda Puglianini, Hien Liu, Taiga Nishihori, Brandon Blue, Frederick Locke, Michael Jain, Ariel Grajales-Cruz, Kenneth Shain, Rachid Baz, Melissa Alsina

Blood (2025) 146 (Supplement 1): 5856.

https://doi.org/10.1182/blood-2025-5856

Published: 2025

Journal Articles

Evolution of t(11;14) biology in multiple myeloma and it's role on outcomes to venetoclax treatment

Praneeth Reddy Sudalagunta, Filip Ionescu, Rafael Renatino Canevarolo, Daniel Deavila, Shrinjaya Thapa, Xiaohong Zhao, Mark Meads, Kenneth Shain, Rachid Baz, Ariel Grajales-Cruz, Ariosto Siqueira Silva

Blood (2025) 146 (Supplement 1): 5730.

https://doi.org/10.1182/blood-2025-5730

Published: 2025

Journal Articles

Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 7454.

https://doi.org/10.1182/blood-2025-7454

Published: 2025

Journal Articles

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 5763.

https://doi.org/10.1182/blood-2025-5763

Published: 2025

Journal Articles

Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium

Blood (2025) 146 (Supplement 1): 137.

https://doi.org/10.1182/blood-2025-137

Published: 2025

Journal Articles

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Ran Reshef, Alexandria Jensen, Christian Gordillo, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Puglianini, Gabriel De Avila, Eli Zolotov, Evguenia Bhurtel, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen, Surbhi Sidana

Blood (2025) 146 (Supplement 1): 134.

https://doi.org/10.1182/blood-2025-134

Published: 2025

Journal Articles

Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)

Danai Dima, Lauren Peres, Leyla Shune, Christelle Leitzinger, Brett Reid, Andrew Portuguese, Raffaella Cassano Cassano, Rahul Banerjee, Nilesh Kalariya, Oren Pasvolsky, Mahmoud Gaballa, Zachary Hunzeker, Christen Dillard, Hitomi Hosoya, Lekha Mikkilineni, Rebecca Gonzalez, Ariel Grajales-Cruz, Omar Alexis Castaneda Puglianini, Taiga Nishihori, Charlotte Wagner, Christopher Cahoon, Douglas Sborov, Evguenia Bhurtel, Jeries Kort, Marcus Geer, Sneha Purvey, Christopher Ferreri, Cindy Varga, Shebli Atrash, Peter Voorhees, Utkarsh Goel, Jack Khouri, Shahzad Raza, Faiz Anwer, Aimaz Afrough, Aishwarya Sannareddy, Larry Anderson, Hamza Hassan, Megan Herr, Ran Reshef, Christian Gordillo, Eli Zolotov, Noa Biran, James Davis, Kimberly Green, Saurabh Zanwar, Yi Lin, Luciano Costa, Susan Bal, Shonali Midha, Omar Nadeem, Melissa Alsina, Rachid Baz, Kenneth Shain, Frederick Locke, Shaji Kumar, Krina Patel, Surbhi Sidana, Doris Hansen

Blood (2025) 146 (Supplement 1): 4000.

https://doi.org/10.1182/blood-2025-4000

Published: 2025

Journal Articles

Dermatologic adverse effects with elranatamab mimicking talquetamab

M Bakri Hammami, Sean Haney, Daniel Deavila, Julia Fadul, Christine Simonelli, Samantha Seitzler, Sairekha Ravichandran, Melissa Alsina, Brandon Blue, Ariel Grajales-Cruz, Rachid Baz, Kenneth Shain

Blood (2025) 146 (Supplement 1): 2200.

https://doi.org/10.1182/blood-2025-2200

Published: 2025

Journal Articles

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Blood (2025) 146 (Supplement 1): 686.

https://doi.org/10.1182/blood-2025-686

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.

Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma

Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma

Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma

Safety and efficacy of talquetamab in patients with relapsed and refractory multiple myeloma (RRMM) with and without renal impairment (RI)

Real world outcomes of bispecific T-cell engagers in plasma cell leukemia

Oral Care™ kit as a prophylaxis for talquetamab-associated toxicities in patients with Relapsed/Refractory multiple myeloma

ClonoSEQ MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma.

Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the auriga study

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Evolution of t(11;14) biology in multiple myeloma and it's role on outcomes to venetoclax treatment

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)

Dermatologic adverse effects with elranatamab mimicking talquetamab

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only